WaveForm Technologies said today that it has finished four clinical trials of its continuous glucose monitoring system and that it expects to win CE Mark clearance for the device this year. The WaveForm CGM system is designed to be worn for 14 days and includes a sensor insertion tool, a small sensor wire, a polymer […]
Research & Development
KemPharm launches pivotal efficacy trial for extended-release ADHD prodrug
KemPharm (NSDQ:KMPH) has launched a pivotal efficacy trial of its extended-release prodrug product for the treatment of attention deficit hyperactivity disorder in children. The company’s classroom-style study is designed to support a potential label for KP415 that would include both early-onset and long duration treatment effect for ADHD. The 140-patient trial is slated to wrap up […]
Denali inks collab with Takeda to help Alzheimer’s drugs get into the brain
Denali Therapeutics (NSDQ:DNLI) has landed a strategic partnership with Takeda Pharmaceutical (TYO:4502) to develop and commercialize three of its product candidates for neurodegenerative diseases. The deal includes Denali’s preclinical Alzheimer’s projects, among other undisclosed candidates, which make use of the company’s antibody transport vehicles, or ATVs, to penetrate the blood-brain barrier. According to the terms of […]
Swiss biotech Oculis raises $21m for nanoparticle eye-drops
Swiss biotech Oculis has raised $21 million in a Series B round backed by investors including Novartis (NYSE:NVS) and Bay City Capital. The company is developing topical drugs for back-of-the-eye diseases, which are normally treated with painful injections directly into the eye. Oculis reported that its newly-acquired funds will be used to support the clinical development of […]
Drug-delivery tech developer AMW lands $30m from EU bank
Drug-delivery tech developer AMW has landed $30 million from the European Union’s lending institution to help fund the company’s development activities and expand production capacity. The German pharmaceutical company’s newly-acquired funds will specifically support a new R&D facility located in Bavaria. The transaction was supported by the European Fund for Strategic Investments. “Supporting research, development […]
The ‘smart pill’ market could be worth $3B by 2025 – meet the key players
The “smart pill” market is expected to nearly quadruple in value to $3 billion by 2025, according to Grand View Research. Driving this growth is an increasing demand for minimally-invasive procedures, as well as better patient monitoring capabilities. There are a number of players in the pharmaceutical and medtech arenas looking to stake a claim […]
These lab-grown blood vessel replacements could benefit dialysis patients
University of Minnesota researchers have developed a blood vessel replacement made of biological materials in a lab. The lab-grown vessels have no living cells at implantation and could be used as a graft for kidney dialysis patients. The lab-engineered blood vessel replacement is the first nonsynthetic, decellularized graft that is repopulated with cells using the […]
Aura Biosciences raises $30m for nanoparticle cancer treatment
Aura Biosciences has closed a $30 million Series C round with funding from new investors like Arix Bioscience and Lundbeckfonden Ventures, as well as existing investors, including the estate of former-Genzyme CEO Henri Termeer, who died earlier this year. The privately-held biotech is developing a light-activated nanoparticle therapy for patients with ocular melanoma. Aura said […]
Mass Innovation Labs expands to give startups a better way to do research
At the 124,000-square foot Cambridge headquarters of Mass Innovation Labs, co-founder & CEO Amrit Chaudhuri points to a cluster of tables and identifies them one by one: This startup went public and did a massive deal with Merck (NYSE:MRK), he says, and sits shoulder-to-shoulder with a different company working on a Phase II clinical asset. More than a […]
IntelGenx to reclaim global rights to oral thin-film migraine treatment
IntelGenx (CVE:IGX) is slated to regain exclusive global rights to develop and sell its Rizaport oral thin-film acute migraine treatment in January, according to a report from BioTuesdays. The company’s partner, RedHill Biopharma (NSDQ:RDHL), has decided to end its co-development and commercialization relationship with IntelGenx, the news site reported. “We were expecting RedHill’s decision because in recent […]
